Evaluation of Medical Technologies with Uncertain Benefits

46 Pages Posted: 16 Mar 2020

See all articles by Darius N. Lakdawalla

Darius N. Lakdawalla

University of Southern California - Schaeffer Center for Health Policy and Economics

Charles Phelps

University of Rochester

Multiple version iconThere are 2 versions of this paper

Date Written: July 2019


Cost-effectiveness analysis (CEA), despite its known limitations, continues as the primary method used for health technology assessment (HTA) both officially (UK, Australia and Canada) and less formally elsewhere. Standard CEA models compare incremental cost increases to incremental average gains in health, commonly expressed in Quality-Adjusted Life Years (QALYs). Our research generalizes earlier CEA models in several ways. First, we introduce risk aversion in Quality of Life (QoL), which affects willingness to pay (WTP) for health care, leading to WTP thresholds that rise with illness severity. Ignoring risk aversion in QoL over-values treatments for minor illnesses and under-values treatments for highly severe illnesses, perhaps by an order of magnitude. We call our generalized WTP threshold the Risk-Aversion and Severity-Adjusted WTP (RASA-WTP). Unlike traditional CEA analyses, which discriminate against persons with disabilities, our analysis implies that the marginal value of improving QoL rises for disabled individuals. Our model can also value the uncertain benefits of medical interventions by employing well-established analytic methods from finance. We develop a certainty-equivalent quality of life measure that we call the Risk-Adjusted QALY (RA-QALY), which accounts for consumer preferences over risky health outcomes. Finally, we show that traditional QALYs no longer serve as a single index of health, when consumers are risk-averse. To address this problem, we derive a generalized single-index of health outcomes—the Generalized Risk-Adjusted QALY (GRA-QALY). The GRA-QALY reinstates the equivalence between health gains from quality of life and gains from life extension, even in the presence of risk-aversion and treatment outcome uncertainty. Earlier models of CEA that abstract from risk-aversion nest as special cases of our more general model. We discuss new data necessary to implement our model and standard analytic methods by which the necessary parameters can be obtained.

Suggested Citation

Lakdawalla, Darius N. and Phelps, Charles, Evaluation of Medical Technologies with Uncertain Benefits (July 2019). NBER Working Paper No. w26058, Available at SSRN: https://ssrn.com/abstract=3554139

Darius N. Lakdawalla (Contact Author)

University of Southern California - Schaeffer Center for Health Policy and Economics ( email )

635 Downey Way
Los Angeles, CA 90089-3333
United States

Charles Phelps

University of Rochester ( email )

300 Crittenden Blvd.
Rochester, NY 14627
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
PlumX Metrics